Robert Hawkins BA, MA, MBBS, PhD, FRCP

Professor Hawkins focuses on treating renal cancer and on developing immunotherapy, particularly cellular immunotherapy. He heads a clinical research group undertaking trials and also a range of early phase clinical trials of biological agents including vaccines, antibody based molecules and cell therapies.
He has successfully led the clinical development of several biological agents from Phase I to Phase III studies. Prof. Hawkins is CEO of Immetacyte Ltd. (formally Cellular Therapeutics Ltd.) a commercial venture which integrates a GMP manufacturing and R&D facility with the capacity to manufacture natural and gene modified T-cell therapies.